公开(公告)号：US20240254219A1

公开(公告)日：2024-08-01

申请号：US18693416

申请日：2022-09-20

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Nam-Kyung LEE ,  Scott BIDLINGMAIER ,  Yang SU

IPC: C07K16/28 ,  A61K39/00 ,  A61P19/10 ,  C12N15/10

CPC classification number: C07K16/28 ,  A61P19/10 ,  C12N15/1037 ,  C12N15/1055 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/75

Abstract: Antibodies are provided herein that agonize Wnt signaling, do not compete with a Wnt ligand for LRP6 binding, and activate Wnt signaling in the presence of inhibitors. Methods for promoting cell differentiation and tissue regeneration using the disclosed antibodies are also provided.

公开(公告)号：US20220411508A1

公开(公告)日：2022-12-29

申请号：US17639225

申请日：2020-09-09

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Shanshan LANG ,  Yang SU ,  Scott BIDLINGMAIER ,  Nam-Kyung LEE

IPC: C07K16/28

Abstract: The present disclosure relates generally to compositions and methods useful for the production of engineered antibodies having (i) multiple antigen-binding specificities and (ii) Fc regions that have been modified to promote heterodimer formation between heavy chains from antibodies with different specificities. Also provided are recombinant cells, recombinant nucleic acids encoding such engineered antibodies, as well as pharmaceutical compositions containing same.

公开(公告)号：US20160096883A1

公开(公告)日：2016-04-07

申请号：US14836734

申请日：2015-08-26

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  James D. MARKS ,  Xiaodong ZHU ,  Scott BIDLINGMAIER

IPC: C07K16/18 ,  A61K47/48 ,  G01N33/574 ,  A61K51/10

CPC classification number: C07K16/18 ,  A61K47/6843 ,  A61K51/1045 ,  C07K16/2896 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92 ,  C12N5/0695 ,  G01N33/57407

Abstract: The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.

Abstract translation: 本公开通常涉及特异性结合多形性胶质母细胞瘤（GBM）细胞的抗体。 特别地，本公开提供了包含结合肿瘤细胞的人单链或全长抗体的组合物。 另外，本公开提供了使用抗GBM抗体的方法。

公开(公告)号：US20240058464A1

公开(公告)日：2024-02-22

申请号：US18260657

申请日：2022-01-06

Applicant: Fortis Therapeutics, Inc. ,  The Regents of the University of California

Inventor： Bin LIU ,  Andrew DORR ,  Jay LICHTER ,  Marc NASOFF ,  Leonard POST

IPC: A61K47/68 ,  A61K31/4196 ,  A61K31/675 ,  A61K31/7068 ,  A61K31/282 ,  A61K31/58 ,  A61K39/395 ,  A61K31/704 ,  A61K31/44 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00

CPC classification number: A61K47/6849 ,  A61K47/68031 ,  A61K47/6889 ,  A61K31/4196 ,  A61K31/675 ,  A61K31/7068 ,  A61K31/282 ,  A61K31/58 ,  A61K39/3955 ,  A61K31/704 ,  A61K31/44 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00

Abstract: Disclosed herein are methods of treating cancer. Some such methods include administration of a first anti-cancer agent that increases CD46 expression on the surface of a cancer cell. Some embodiments include administration of a second anti-cancer agent that binds CD46. The second anti-cancer agent may include an immunoconjugate comprising a CD46 binding domain and effector agent.

公开(公告)号：US20130295684A1

公开(公告)日：2013-11-07

申请号：US13726520

申请日：2012-12-24

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Guillermo C. BAZAN ,  Bin LIU

IPC: C08G61/02

CPC classification number: C08G61/02 ,  C08G61/122 ,  C08G61/123 ,  C12Q1/6818 ,  C12Q1/6837 ,  G01N21/6428 ,  G01N21/6452 ,  G01N2021/6419 ,  G01N2021/6439 ,  C12Q2563/131 ,  C12Q2537/119 ,  C12Q2525/107

Abstract: Disclosed are multichromophores, and methods, articles and compositions employing them. Disclosed are methods, articles and compositions for the detection and analysis of biomolecules in a sample. Provided assays include those determining the presence of a target biomolecule in a sample or its relative amount, or the assays may be quantitative or semi-quantitative. The methods can be performed on a substrate or in an array format on a substrate. Disclosed are detection assays employing sensor biomolecules that do not comprise a fluorophore that can exchange energy with the cationic multichromophore. Disclosed are biological assays in which energy is transferred between one or more of the multichromophore, a label on the target biomolecule, a label on the sensor biomolecule, and/or a fluorescent dye specific for a polynucleotide, in all permutations.

Abstract translation: 公开了多重色谱和其使用它们的方法，制品和组合物。 公开了用于检测和分析样品中生物分子的方法，制品和组合物。 提供的测定包括确定样品中靶生物分子的存在或其相对量的那些，或者测定可以是定量或半定量的。 该方法可以在衬底上以阵列形式在衬底上进行。 公开了使用不包含可与阳离子多重色素交换能量的荧光团的传感器生物分子的检测测定。 公开了在所有排列中能量在一个或多个多色素，目标生物分子上的标记，传感器生物分子上的标记和/或多核苷酸特异的荧光染料之间转移能量的生物测定。

公开(公告)号：US20220177534A1

公开(公告)日：2022-06-09

申请号：US17053872

申请日：2019-05-10

Applicant: The Regents of the University of California ,  The United States Government Represented by the Department of Veterans Affairs

Inventor： Steven M. DUBINETT ,  Jay Moon LEE ,  Bin LIU ,  Ramin SALEHI-RAD ,  Sharvendra SHARMA

IPC: C07K14/52 ,  C07K14/705

Abstract: The present disclosure relates, in general, to methods for treating cancer comprising administering to a subject in need thereof an effective amount of dendritic cells comprising the human CCL21 gene in combination with an anti-PD-1 antibody. In one aspect, the treatment is amenable to patients with tumors having a high mutational burden.

公开(公告)号：US20220002432A1

公开(公告)日：2022-01-06

申请号：US17293258

申请日：2019-11-15

Applicant: Virtuoso BINco, Inc. ,  The Regents of the University of California

Inventor： Bin LIU ,  Xiaocheng CHEN ,  Scott BIDLINGMAIER ,  Leonard POST ,  Yang SU ,  Namkyung LEE

IPC: C07K16/28 ,  A61K45/06

Abstract: Disclosed herein are anti-CD38 antibodies, anti-ICAM1 antibodies, pharmaceutical compositions comprising anti-CD38 antibodies and/or anti-ICAM1 antibodies, and methods of use for the treatment of a proliferative disease. In certain embodiments, also disclosed herein are multi-specific antibodies (e.g., bispecific antibodies) comprising a first targeting moiety that specifically binds to CD38 and a second targeting moiety that specifically binds to ICAM1, pharmaceutical compositions comprising the multi-specific antibodies, and methods of use for the treatment of a proliferative disease.

公开(公告)号：US20220280609A1

公开(公告)日：2022-09-08

申请号：US17625062

申请日：2020-07-17

Applicant: The Regents of the University of California ,  United States Government Represented by the Department of Veterans Affairs

Inventor： Steven M. DUBINETT ,  Bin LIU ,  Raymond LIM ,  Ramin SALEHI-RAD

IPC: A61K38/19 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06

Abstract: The present disclosure relates, in general, to methods for treating cancer comprising administering to a subject in need thereof an effective amount of CXCL9, CXCL10 or the combination, in combination with an immune checkpoint inhibitor. The CXCL9, CXCL10 or combination may be administered as a polypeptide, a polynucleotide or cells comprising a polynucleotide encoding CXCL9, CXCL10 or both. In one aspect, the treatment is amenable to patients with low or high mutational burden tumors.

公开(公告)号：US20240374748A1

公开(公告)日：2024-11-14

申请号：US18666551

申请日：2024-05-16

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Scott BIDLINGMAIER ,  Yang SU

IPC: A61K47/68 ,  A61K35/00 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  C12N9/16 ,  G01N33/574

Abstract: This invention provides antibodies directed against a highly specific and previously unrecognized marker for cancerous cells. In certain embodiments an isolated antibody or fragment thereof that specifically binds human placentally expressed ALPP and/or ALPPL2, but not ALPL and ALPI that are expressed outside the placenta is provided as well as immunoconjugates comprising such antibodies.

公开(公告)号：US20240076399A1

公开(公告)日：2024-03-07

申请号：US18183042

申请日：2023-03-13

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Namkyung LEE ,  Yang SU ,  Scott BIDLINGMAIER

IPC: C07K16/30 ,  A61K31/713 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/30 ,  A61K31/713 ,  C07K16/2821 ,  C07K16/2866 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure relates to an engineered antibody that co-engages a cell type-selective (or specific) antigen (guide) and a signaling receptor (effector) on a target cell. In some instances, the engineered antibody is capable of modulating a signaling pathway on a target cell. In other embodiments, an engineered antibody of the present disclosure is administered to a subject for the treatment of a disease or condition.